Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knowledge, Perceptions, and Barriers to Collection of Family Health History Data.

Journal of the American Board of Family Medicine : JABFM·2026
Same author

Receipt, knowledge, and interest in genetic testing for cancer - National Center for Health Statistics Rapid Surveys System, United States, January-February 2024.

Annals of epidemiology·2026
Same author

Algorithm for azoospermic men with normal follicle stimulating hormone (FSH) levels and an unclear clinical diagnosis of obstructive versus non-obstructive azoospermia.

Translational andrology and urology·2026
Same author

When structure mattered more than authorship: Lessons from developing a generative AI Tool for high-stakes multiple-choice question generation.

Medical education·2026
Same author

Decline in Applicants to Obstetrics and Gynecology Fellowships: Influence on Match Rates and Competitiveness.

O&G open·2026
Same author

Surgical interventions to optimize fertility.

Fertility and sterility·2026

Related Experiment Video

Updated: Jun 24, 2026

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
05:56

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells

Divya K Shah1, K M J Menon, Lourdes M Cabrera

  • 1Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 48109, USA. divyas@med.umich.edu

Fertility and Sterility
|April 4, 2009
PubMed
Summary

Thiazolidenedione derivatives (TZDs) like ciglitazone reduced vascular endothelial growth factor (VEGF) in human cells. Pioglitazone did not harm mouse embryo development, suggesting TZDs may treat ovarian hyperstimulation syndrome.

Related Experiment Videos

Last Updated: Jun 24, 2026

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
05:56

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts

Published on: January 22, 2020

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Pharmacology

Background:

  • Vascular Endothelial Growth Factor (VEGF) plays a critical role in angiogenesis and is implicated in ovarian hyperstimulation syndrome (OHSS).
  • Thiazolidenedione derivatives (TZDs) are a class of drugs with known effects on cellular signaling pathways.

Purpose of the Study:

  • To investigate the impact of TZDs on VEGF production by human granulosa cells.
  • To assess the effect of TZDs on the in vitro development of murine embryos.

Main Methods:

  • Human granulosa cells were treated with ciglitazone in the presence or absence of hCG.
  • Murine embryos were cultured with pioglitazone.
  • VEGF levels and embryo morphology were measured.

Main Results:

  • Ciglitazone significantly reduced VEGF production by human granulosa cells.
  • Pioglitazone did not adversely affect murine blastocyst development.

Conclusions:

  • TZDs, specifically ciglitazone, can decrease VEGF production in human granulosa cells.
  • Pioglitazone appears safe for early embryo development.
  • TZDs warrant further investigation as a potential therapeutic strategy for OHSS.